Skip to content

CVS Health to acquire Signify Health in an $8 billion deal, or $30.50 per share

CVS Health to acquire Signify Health in an $8 billion deal, or $30.50 per share
Dino Kurbegovic

On September 5, CVS Health (NYSE: CVS) agreed to acquire Signify Health (NYSE: SGFY) for $30.50 per share in cash, for a total transaction value of roughly $8 billion. Notably, CVS beat out other potential buyers, including Amazon (NASDAQ: AMZN) and UnitedHealth (NYSE: UNH).

This new deal will allow CVS to coordinate medical care for millions of Americans through 10,000 contracted doctors and clinicians across 50 states. Furthermore, CVS Health President and CEO Karen S. Lynch claimed that the combination of these two entities would enhance their connection to consumers. 

“This acquisition will enhance our connection to consumers in the home and enables providers to better address patient needs as we execute our vision to redefine the health care experience. In addition, this combination will strengthen our ability to expand and develop new product offerings in a multi-payor approach.”

CVS chart and analysis

CVS is part of the Health Care Providers & Services industry, with 127 other stocks in this industry, it outperforms 87% of them. Over the past month, the stock traded from $97.75 to $107.26, closing above the 50-day moving average

Further, the technical analysis shows a support line at $92.87 and a resistance line at $106.61.  

CVS 20-50-200 SMA lines chart. Source. Finviz.com data. See more stocks here.

TipRanks analysts rate the shares a ‘strong buy,’ seeing the average price in the next 12 months reaching $122.33, 23.02% higher than the current trading price of $99.44. Out of the 12 TipRanks analysts covering the stock, ten have a ‘buy,’ and only two have a ‘hold’ rating.

Wall Street analysts’ price targets for CVS. Source: TipRanks  

Innovation experts.

With this acquisition, CVS keeps piling on innovation and showing that they’re a responsible custodian of human health, which was confirmed by their more recent acquisition of green, renewable energy from Constellation (NASDAQ: CEG), a 15-year commitment by CVS. 

All in all, CVS is becoming a healthcare behemoth in its industry, with a 2.21% dividend yield, or $0.55 quarterly per share, it could find its place on the list of dividend investors’ potential plays.   

Buy stocks now with Interactive Brokers – the most advanced investment platform


Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk. 

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.